On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup Inc. and its affiliates through the execution of a series of agreements designed to advance the development and commercialization of the Company's intranasal Epinephrine program. The Company and AptarGroup Inc. have a history of collaboration dating back to 2019. On October 6, 2025, the Company and AptarGroup, Inc. ("Aptar") entered into a Termination and Settlement Agreement (the "Termination Agreement") to: (i) terminate that certain Master Services Agreement by and between the Company and Aptar entered into on September 6, 2019 (the "2019 Aptar MSA); (ii) terminate the schedules of work relating to the Company's Epinephrine program (the "2025 SOW"), and a short-form supply agreement (the "Supply Agreement").
The 2025 Aptar MSA replaces the 2019 Aptar MSA and updates terms and conditions under which Aptar will provide development, analytical, regulatory, and consulting services to the Company, including services enumerated in schedules of work signed by the parties for fees set forth in such schedules. The 2025 Aptar M SA includes customary provisions regarding confidentiality, intellectual property, indemnification, and termination rights. The 2025 AptarMSA remains in effect until the later date of five years from the signing date, or until the services are completed.
Pursuant to the 2025 Aptar MSA, the parties entered into a schedule of work related to Epinephrine on October 6, 2025. Under the 2025 SOW, Aptar France will provide support for the development, testing, and regulatory submission of the Company's intran as a intranasal Epine®? powder delivered through Aptar's Unit Dose Powder nasal delivery system ("UDSp") device.
In consideration for such services, the Company has agreed to pay Aptar France stored fees over the next three years, milestone payments upon (i) new drug application ("NDA") submission and (ii) NDA approval, and royalties stemming from commercial sales of the intranasal Epine injects. The Supply Agreement provides that, subject to U.S. Food and Drug Administration approval of the underlying program, Aptar France will exclusively supply the Company with UDSp devices, with the Company committing to purchase 100% of its requirements from Aptar France for use in its products for Epinephrine. The Supply Agreement has an initial term of five years, is renewable for two years, and sets forth pricing on a per-component basis.
